Amgen tops Q4 earnings, touts Repatha cardiovascular outcomes

Shares in Amgen (NSDQ:AMGN) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results and touted data from a trial for its cholesterol drug, Repatha.

The Thousand Oaks, Calif.-based company posted profits of $1.94 billion, or $2.59 per share, on sales of $5.97 billion for the 3 months ended Dec. 31, for bottom-line growth of 8% on sales growth of 8% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $2.89, ahead of consensus on The Street, where analysts were looking for sales of $5.74 billion.

Get the full story at our sister site, Drug Delivery Business News.

The post Amgen tops Q4 earnings, touts Repatha cardiovascular outcomes appeared first on MassDevice.

from MassDevice http://ift.tt/2jLUFdy